Home LiteratureArticle Details
PMID: 24644022 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures.

Arthritis & rheumatology (Hoboken, N.J.) ·Vol. 66 ·No. 6 ·2014-06-00 ·Pages 1583-95

Chiche L, Jourde-Chiche N, Whalen E, Presnell S, Gersuk V, Dang K, Anguiano E, Quinn C, Burtey S, Berland Y, Kaplanski G, Harle JR, Pascual V, Chaussabel D

Abstract

The role of interferon-α (IFNα) in the pathogenesis of systemic lupus erythematosus (SLE) is strongly supported by gene expression studies. The aim of this study was to improve characterization of the blood IFN signature in adult SLE patients. Consecutive patients were enrolled and followed up prospectively. Microarray data were generated using Illumina BeadChips. A modular transcriptional repertoire was used as a framework for the analysis. Our repertoire of 260 modules, which consisted of coclustered gene sets, included 3 IFN-annotated modules (M1.2, M3.4, and M5.12) that were strongly up-regulated in SLE patients. A modular IFN signature was observed in 54 of 62 patients (87%) or 131 of all 157 samples (83%). The IFN signature was more complex than expected, with each module displaying a distinct activation threshold (M1.2 < M3.4 < M5.12), thus providing a modular score by which to stratify SLE patients based on the presence of 0, 1, 2, or 3 active IFN modules. A similar gradient in modular IFN signature was observed within patients with clinically quiescent disease, for whom moderate/strong modular scores (2 or 3 active IFN modules) were associated with higher anti-double-stranded DNA titers and lower lymphocyte counts than those in patients with absent/mild modular scores (0 or 1 active IFN modules). Longitudinal analyses revealed both stable (M1.2) and variable (M3.4 and M5.12) components of modular IFN signature over time in single patients. Interestingly, mining of other data sets suggested that M3.4 and M5.12 could also be driven by IFNβ and IFNγ. Modular repertoire analysis reveals complex IFN signatures in SLE, which are not restricted to the previous IFNα signature, but which also involve IFNβ and IFNγ.

MeSH Terms
Adolescent Adult Aged Biomarkers/metabolism Female Follow-Up Studies Gene Expression Profiling/methods Humans Interferon Type I/genetics,metabolism Interferon-alpha/genetics,metabolism Interferon-beta/genetics,metabolism Interferon-gamma/genetics,metabolism Lupus Erythematosus, Systemic/genetics,metabolism Male Middle Aged Prospective Studies Young Adult
Chemicals
Biomarkers Interferon Type I Interferon-alpha Interferon-beta Interferon-gamma
Authors & Affiliations
14 authors, click to expand affiliations / ORCID
Chiche Laurent
Benaroya Research Institute, Seattle, Washington, and Aix-Marseille University and Hôpital de la Conception, APHM, Marseille, France.
Jourde-Chiche Noémie
Whalen Elizabeth
Presnell Scott
Gersuk Vivian
Dang Kristen
Anguiano Esperanza
Quinn Charlie
Burtey Stéphane
Berland Yvon
Kaplanski Gilles
Harle Jean-Robert
Pascual Virginia
Chaussabel Damien
References (48)
48 references, click to expand
  1. Reversible inhibition of murine cytomegalovirus replication by gamma interferon (IFN-γ) in primary macrophages involves a primed type I IFN-signaling subnetwork for full establishment of an immediate-early antiviral state.
    J Virol. 2011 Oct;85(19):10286-99 PMID: 21775459
  2. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases.
    PLoS One. 2012;7(1):e29161 PMID: 22235269
  3. Interferome v2.0: an updated database of annotated interferon-regulated genes.
    Nucleic Acids Res. 2013 Jan;41(Database issue):D1040-6 PMID: 23203888
  4. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.
    Arthritis Rheum. 2013 Apr;65(4):1011-21 PMID: 23400715
  5. Current perspectives on systems immunology approaches to rheumatic diseases.
    Arthritis Rheum. 2013 Jun;65(6):1407-17 PMID: 23450649
  6. Validity of clinical associations of biomarkers in translational research studies: the case of systemic autoimmune diseases.
    Arthritis Res Ther. 2010;12(5):R179 PMID: 20875104
  7. Circos: an information aesthetic for comparative genomics.
    Genome Res. 2009 Sep;19(9):1639-45 PMID: 19541911
  8. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines.
    Immunity. 2013 Apr 18;38(4):831-44 PMID: 23601689
  9. Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis.
    PLoS One. 2011;6(8):e23634 PMID: 21886806
  10. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases.
    Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17609-14 PMID: 23045702
  11. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
    Arthritis Rheum. 2009 Jun;60(6):1785-96 PMID: 19479852
  12. A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis.
    J Am Acad Dermatol. 2010 Mar;62(3):427-36 PMID: 20159310
  13. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood.
    J Exp Med. 2003 Mar 17;197(6):711-23 PMID: 12642603
  14. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.
    Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2610-5 PMID: 12604793
  15. Biomarkers for systemic lupus erythematosus.
    Transl Res. 2012 Apr;159(4):326-42 PMID: 22424435
  16. Type I interferon and autoimmune disease.
    Autoimmunity. 2003 Dec;36(8):445-6 PMID: 14984020
  17. Anti-interferon alpha treatment in SLE.
    Clin Immunol. 2013 Sep;148(3):303-12 PMID: 23566912
  18. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis.
    Nature. 2010 Aug 19;466(7309):973-7 PMID: 20725040
  19. Roles of interferon-gamma and interleukin-4 in murine lupus.
    J Clin Invest. 1997 Apr 15;99(8):1936-46 PMID: 9109438
  20. Immunomodulatory functions of type I interferons.
    Nat Rev Immunol. 2012 Jan 06;12(2):125-35 PMID: 22222875
  21. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Arthritis Rheum. 2013 Aug;65(8):2143-53 PMID: 23754628
  22. A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity.
    Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20446-51 PMID: 19074283
  23. Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment.
    J Transl Med. 2008 Nov 05;6:66 PMID: 18986530
  24. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus.
    Lupus. 2009 Oct;18(11):980-9 PMID: 19762399
  25. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway.
    Ann Rheum Dis. 2011 Nov;70(11):2029-36 PMID: 21803750
  26. Classification and definition of major flares in SLE clinical trials.
    Lupus. 1999;8(8):685-91 PMID: 10568907
  27. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus.
    Ann Rheum Dis. 2009 Sep;68(9):1440-6 PMID: 18772188
  28. The interferon signature in autoimmune diseases.
    Curr Opin Rheumatol. 2013 Mar;25(2):248-53 PMID: 23249830
  29. Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells.
    Arthritis Rheum. 2009 May;60(5):1463-71 PMID: 19404947
  30. Genomic analysis of the host response to hepatitis C virus infection.
    Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15669-74 PMID: 12441396
  31. A genomic approach to human autoimmune diseases.
    Annu Rev Immunol. 2010;28:535-71 PMID: 20192809
  32. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus.
    Immunity. 2008 Jul 18;29(1):150-64 PMID: 18631455
  33. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers.
    PLoS One. 2013 Aug 05;8(8):e70630 PMID: 23940611
  34. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
    Arthritis Rheum. 2005 May;52(5):1491-503 PMID: 15880830
  35. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus.
    Ann Rheum Dis. 2008 Aug;67(8):1069-75 PMID: 18063674
  36. Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B.
    J Immunol. 2008 Aug 1;181(3):2211-9 PMID: 18641361
  37. Microarray analysis of interferon-regulated genes in SLE.
    Autoimmunity. 2003 Dec;36(8):481-90 PMID: 14984025
  38. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus.
    Nature. 2010 Jun 17;465(7300):937-41 PMID: 20559388
  39. Systematic identification of type I and type II interferon-induced antiviral factors.
    Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4239-44 PMID: 22371602
  40. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
    Arthritis Rheum. 2006 Sep;54(9):2951-62 PMID: 16947629
  41. Functional crosstalk between type I and II interferon through the regulated expression of STAT1.
    PLoS Biol. 2010 Apr 27;8(4):e1000361 PMID: 20436908
  42. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.
    Arthritis Rheum. 2009 Oct;60(10):3098-107 PMID: 19790071
  43. Linear models and empirical bayes methods for assessing differential expression in microarray experiments.
    Stat Appl Genet Mol Biol. 2004;3:Article3 PMID: 16646809
  44. Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis.
    Ann Rheum Dis. 2010 Jun;69(6):1208-13 PMID: 19815495
  45. Fifty years of anti-ds DNA antibodies: are we approaching journey's end?
    Rheumatology (Oxford). 2007 Jul;46(7):1052-6 PMID: 17500073
  46. Host responses to melioidosis and tuberculosis are both dominated by interferon-mediated signaling.
    PLoS One. 2013;8(1):e54961 PMID: 23383015
  47. IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB x NZW)F1 mice.
    J Immunol. 1998 Apr 15;160(8):3713-8 PMID: 9558072
  48. Meta-analysis of microarray data using a pathway-based approach identifies a 37-gene expression signature for systemic lupus erythematosus in human peripheral blood mononuclear cells.
    BMC Med. 2011 May 30;9:65 PMID: 21624134
Article Info
Journal
Arthritis & rheumatology (Hoboken, N.J.)
Abbr.
Arthritis Rheumatol
ISSN
2326-5205
Published
2014-06-00
Pages
1583-95
Language
English
Region
United States
NLM ID
101623795
PMCID
PMC4157826
Subset
IM
Grants
NIAID NIH HHS · U19 AI082715 · United States
Databases
ClinicalTrials.gov
NCT00920114
Corrections
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]